Madrigal Pharmaceuticals, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- William J. Sibold
- Full Time Employees
- 915
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Four Tower Bridge West Conshohocken PA United States of America 19428
- IPO Date
- Feb 6, 2007
- CIK
- 0001157601
- Website
- madrigalpharma.com
- Similar Companies
- Business
- Madrigal Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing innovative therapies for severe liver conditions. The company's primary focus lies in metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), a disease with considerable unmet medical needs. Its leading therapeutic, Rezdiffra (resmetirom), an oral, liver-directed selective thyroid hormone receptor-β agonist, received accelerated approval from the U.S. Food and Drug Administration in March 2024 for adults with noncirrhotic MASH featuring moderate to advanced liver fibrosis. Rezdiffra has also secured approval from the European Commission for this indication. Madrigal continues to advance its clinical program, evaluating Rezdiffra in an ongoing Phase 3 outcomes trial for patients with compensated MASH cirrhosis. Additionally, the company is progressing an oral GLP-1 development candidate, MGL-2086, slated to enter clinical trials in early 2026, with potential for combination therapy alongside Rezdiffra. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Madrigal's Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands
John Paulson's Top Q2 2026 Move: Exiting Agnico Eagle Mines Ltd at a -5.11% Portfolio Impact
Madrigal Appoints John C. Reed, M.D.
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Apple, CoreWeave, eBay, Exxon Mobil, Intuit, Nebius Group, Palantir Technologies, SK hynix, and More
MDGL Stock Down Despite Q2 Beat, MASH Drug Drives Top-Line Y/Y Growth
Madrigal Pharmaceuticals Q2 Earnings Call Highlights
Madrigal Pharmaceuticals, Inc. (MDGL) Q2 2026 Earnings Call Transcript
Madrigal (MDGL) Reports Q2 Loss, Beats Revenue Estimates
Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026
Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio
3 Under-the-Radar Stocks to Buy and Hold
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Ribo y Madrigal alcanzan un primer hito importante en el avance de nuevas terapias con siRNA para MASH
Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)